This is a working overview of synaptic plasticity, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-07-28 and is reviewed periodically as new material appears.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
== Signs and symptoms == Trauma from a gunshot wound varies widely based on the bullet, velocity, mass, entry point, trajectory, affected anatomy, and exit point. Gunshot wounds can be particularly devastating compared to other penetrating injuries because the trajectory and fragmentation of bullets can be unpredictable after entry. Moreover, gunshot wounds typically involve a large degree of nearby tissue disruption and destruction caused by the physical effects of the projectile correlated with the bullet velocity classification. The immediate damaging effect of a gunshot wound is typically severe bleeding with the potential for a type of shock known as hypovolemic shock, a condition characterized by inadequate delivery of oxygen to vital organs. In the case of traumatic hypovolemic shock, this failure of adequate oxygen delivery is due to blood loss, as blood is the means of delivering oxygen to the body's constituent parts. Besides blood loss, internal bleeding can lead to complications. Devastating effects can result when a bullet strikes a vital organ such as the heart, lungs, or liver, or damages a component of the central nervous system such as the spinal cord or brain. It can lead to organ failure and death. Common causes of death following gunshot injury include bleeding, low oxygen caused by pneumothorax, catastrophic injury to the heart and major blood vessels, and damage to the brain or central nervous system.
=== Power differential DSC === For this kind of setup, also known as Power compensating DSC, the sample and reference crucible are placed in thermally insulated furnaces and not next to each other in the same furnace as in heat-flux-DSC experiments. Then the temperature of both chambers is controlled so that the same temperature is always present on both sides. The electrical power that is required to obtain and maintain this state is then recorded rather than the temperature difference between the two crucibles.
Several studies have shown that doxycycline inhibits dopaminergic neurodegeneration through the upregulation of axonal and synaptic proteins. Axonal degeneration and synaptic loss are key events at the early stages of neurodegeneration and precede neuronal death in neurodegenerative diseases, including Parkinson's disease (PD). Therefore, the regeneration of the axonal and synaptic network might be beneficial in PD. It has been demonstrated that doxycycline mimics nerve growth factor (NGF) signaling in PC12 cells. However, the involvement of this mechanism in the neuroprotective effect of doxycycline is unknown. Doxycycline is also studied in reverting inflammatory changes related to depression. While there is some research on the use of doxycycline for treating major depressive disorder, the results are mixed. After a large-scale trial showed no benefit of using doxycycline in treating COVID‑19, the UK's National Institute for Health and Care Excellence (NICE) updated its guidance to not recommend the medication for the treatment of COVID‑19. Doxycycline was expected to possess anti-inflammatory properties that could lessen the cytokine storm associated with a SARS-CoV-2 infection, but the trials did not demonstrate the expected benefit. Researchers also believed that doxycycline possesses anti-inflammatory and immunomodulatory effects that could reduce the production of cytokines in COVID-19, but these supposed effects failed to improve the outcome of COVID-19 treatment.
=== Pharmacokinetics === The bioavailability of tianeptine is approximately 99%. Its plasma protein binding is about 95%. The metabolism of tianeptine is hepatic, via β-oxidation. CYP enzymes are not involved, which limits the potential for drug-drug interactions. Maximal concentration is reached in about an hour and the elimination half-life is 2.5 to 3 hours. The elimination half-life has been found to be increased to 4 to 9 hours in the elderly. Tianeptine is usually packaged as a sodium salt but can also be found as tianeptine sulfate, a slower-releasing formulation patented by Janssen in 2012. In 2022 Tonix Pharmaceuticals received permission from the US FDA to conduct phase II clinical trials on tianeptine hemioxalate extended-release tablets designed for once-daily use. The project was discontinued in late 2023 because of disappointing results in clinical trials. Tianeptine has two active metabolites, MC5 (a pentanoic acid derivative of the parent compound) and MC3 (a propionic acid derivative). MC5 has a longer elimination half-life of approximately 7.6 hours, and takes about a week to reach steady-state concentration under daily-dosing. MC5 is a mu-opioid agonist but not delta-opioid agonist, with EC50 at the mu-opioid receptor of 0.545 μM (vs 0.194 μM for tianeptine). MC3 is a very weak mu-opioid agonist, with an EC50 of 16 μM. Tianeptine is excreted 65% in the urine and 15% in feces.
In the second reaction, an α-amino acid, or an ester of it, is reduced by sodium amalgam and ethanolic HCl to give an α-amino aldehyde. This process is conceptually similar to the Bouveault–Blanc reduction except that it stops at the aldehyde stage rather than reducing the ester all the way to two alcohols.
Sources: en.wikipedia.org
== June 1, 1915 (Tuesday) == Gorlice–Tarnów Offensive — German infantry occupied three large forts around Przemyśl after a Russian counterattack failed. British light cruiser HMS Arethusa encountered a German airship on the North Sea and quickly launched a Sopwith seaplane to intercept. However, the pilot mistook smoke from British destroyers as a recall signal and abandoned the chase, ending one of the most promising early opportunities for the interception of an airship by a shipborne aircraft. The 107th Infantry Division of the Imperial German Army was established. The United States Department of the Navy awarded its first contract for an airship to the Connecticut Aircraft Company. Shinano Railway extended the Ōito Line in the Nagano Prefecture, Japan, with station Hakuyachō serving the line. As well, the Geibi Railway extended the Geibi Line in the Okayama Prefecture, Japan, with station Miyoshi serving the line. The second part of the Mandra–Bhaun Railway opened in British India (now Pakistan), connecting Mandra with Bhaun. The Sunset Beach Hotel opened in Glenwood Township, Pope County, Minnesota. It was added to the National Register of Historic Places in 1982.
subcellular localization 1. The subdivision of the interior of a cell into functionally distinct spaces or compartments (e.g. membrane-bound organelles) and the delegation of particular cellular functions and activities to these particular spaces. 2. The determination by any of various laboratory methods (e.g. fluorescent labelling) of the precise location(s) within a cell where a specific molecule has occupancy, or at which a specific activity occurs.
Carbon nanotubes can be functionalized to attain desired properties for use in a wide variety of applications. The two main methods of carbon nanotube functionalization are covalent and non-covalent modification. Because of their apparent hydrophobic nature, carbon nanotubes tend to agglomerate, hindering their dispersion in solvents or viscous polymer melts. The resulting nanotube bundles or aggregates reduce the mechanical performance of the final composite. The surface of the carbon nanotubes can be modified to reduce the hydrophobicity and improve interfacial adhesion to a bulk polymer. Chemical routes such as covalent functionalization have been studied extensively, which involves the oxidation of CNTs via strong acids (e.g. sulfuric acid, nitric acid, or a mixture of both) in order to bond the carboxylic groups to the surface of the CNTs as the final product or for further modification by esterification or amination. Free radical grafting is a promising technique among covalent functionalization methods, in which alkyl or aryl peroxides, substituted anilines, and diazonium salts are used as the starting agents. Functionalization can improve CNTs characteristically weak dispersibility in many solvents, such as water - a consequence of their strong intermolecular p–p interactions. This can enhance the processing and manipulation of insoluble CNTs, rendering them useful for synthesizing innovative CNT nanofluids with properties that are tunable for a wide range of applications.
==== Companion of the Order of the Bath (CB) ==== Military Rear Admiral Andrew Betton, , Royal Navy, C033663C. Rear Admiral James David Morley, Royal Navy, C034410Y Major General Kevin Mark Copsey, , 533047. Major General John Robert Mead, , 537468. Air Vice-Marshal Nigel James Colman, , Royal Air Force, 8304546T. Air Marshal Ian David Gale, , Royal Air Force, 8304212Q. Civil Ruth Léonie Hannant, Director General, Policy, Department for Culture, Media and Sport. For Public Service. Liam Cledwyn Laurence Smyth, Clerk of Legislation, House of Commons. For services to Parliament. Jonathan Marron, Director General, Office of Health Inequalities and Disparities, Department of Health and Social Care. For services to Public Health. Lee McDonough, Director General, Net Zero, Nuclear and International, Department for Energy Security and Net Zero. For services to Energy and Climate. Simon Millhouse, Ministry of Defence. For services to Defence. Neil Brendan O'Connor, , lately Director, Building Safety Programme, Department for Levelling Up, Housing and Communities. For services to Building Safety. Polly Theresa Payne, Director General, Policy, Department for Culture, Media and Sport. For Public Service. Sir Arthur Gareth Ludovic Emrys Rhys Williams, , Government Chief Commercial Officer, Cabinet Office. For Public Service. Kenneth Andrew Lyons Thomson, lately Director General, Scottish Government. For Public Service. Brendan Peter Threlfall, , Director General, Union and Windsor Framework, Cabinet Office. For Public Service. Dr Abigail Tierney, lately Director General, Home Office.
Sources: en.wikipedia.org
Since 1953, six Nobel prizes have been awarded in the area of polymer science, excluding those for research on biological macromolecules. This further testifies to its impact on modern science and technology. As Lord Todd summarised in 1980, "I am inclined to think that the development of polymerization is perhaps the biggest thing that chemistry has done, where it has had the biggest effect on everyday life".
=== Extraterrestrial pathogens === Hoyle and Wickramasinghe have advanced the argument that various outbreaks of illnesses on Earth are of extraterrestrial origins, including the 1918 flu pandemic and certain outbreaks of polio and mad cow disease. For the 1918 flu pandemic they hypothesised that cometary dust brought the virus to Earth simultaneously at multiple locations—a view almost universally dismissed by external experts on this pandemic. On 24 May 2003 The Lancet published a letter from Wickramasinghe, jointly signed by Milton Wainwright and Jayant Narlikar, in which they hypothesised that the virus that causes severe acute respiratory syndrome (SARS) could be extraterrestrial in origin instead of originating from chickens. The Lancet subsequently published three responses to this letter, showing that the hypothesis was not evidence-based, and casting doubts on the quality of the experiments referenced by Wickramasinghe in his letter. Claims connecting terrestrial disease and extraterrestrial pathogens have been rejected by the scientific community. In 2020, Wickramasinghe and colleagues published a paper claiming that Severe acute respiratory syndrome coronavirus 2, the virus responsible for the COVID-19 pandemic was also of extraterrestrial origin, the claim was criticised for lacking evidence.
10 mm (0.4 in) – it has well-defined gill arches and has a thin ventral finfold 21 mm (0.8 in) – dorsal and pelvic fin buds appear 33 mm (1.3 in) – embryo has protruding eyes and well-developed gill filaments 43 mm (1.7 in) – it has lost its translucency and develops slits in the egg case, allowing fluid exchange from surrounding seawater and the interior 58 mm (2.3 in) – the finfold starts to decay 66 mm (2.6 in) – the finfold and gill filaments are reduced or absent 74 mm (2.9 in) – external appearance is complete but yolk sac is still being absorbed 100–110 mm (3.9–4.3 in) – hatching
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.